Oramed Pharmaceuticals Inc.
ORMP
$3.65
$0.010.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 38.31M | 10.01M | 48.40M | 13.29M | -7.64M |
| Total Depreciation and Amortization | 30.00K | 30.00K | 31.00K | 30.00K | 30.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -49.08M | -11.14M | -59.63M | -14.21M | 5.67M |
| Change in Net Operating Assets | 7.82M | 639.00K | 9.58M | -2.64M | -1.57M |
| Cash from Operations | -2.92M | -466.00K | -1.63M | -3.54M | -3.52M |
| Capital Expenditure | -5.00K | -2.00K | 0.00 | -4.00K | -3.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.48M | -1.68M | 38.36M | -54.85M | 23.62M |
| Cash from Investing | -19.49M | -1.68M | 38.36M | -54.85M | 23.62M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -4.01M | -361.00K | -371.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -10.36M | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -10.36M | -4.01M | -361.00K | -371.00K | -- |
| Foreign Exchange rate Adjustments | 22.00K | -73.00K | 4.00K | 40.00K | -1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.75M | -6.23M | 36.38M | -58.72M | 20.10M |